Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.84 HKD | +4.67% |
|
-.--% | +35.54% |
05-24 | Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation | MT |
05-24 | Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+35.54% | 1.31B | |
+2.52% | 92.1B | |
-2.63% | 37.92B | |
-13.57% | 32.97B | |
+75.60% | 27.92B | |
-12.73% | 16.14B | |
-2.15% | 14.1B | |
-11.93% | 11.66B | |
+177.66% | 10.29B | |
-50.94% | 9.99B |
- Stock Market
- Equities
- 2696 Stock
- News Shanghai Henlius Biotech, Inc.
- Henlius Biotech Gets China Approval for New Indications of Arthritis Drug